Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Safety and efficacy of MB-106 for the treatment of R/R FL

Mazyar Shadman • 10 Jun 2022
EHA 2022
Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma CAR-T MB-106

Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center, Seattle, WA, talks on the safety and efficacy of MB-106, a third-generation CD20-targeted CAR T-Cell therapy for the treatment of relapsed/refractory (R/R) follicular lymphoma (FL). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Mazyar Shadman

1:17
Dose reductions to manage AEs of ibrutinib treatment for CLL
Mazyar Shadman • 10 Dec 2023
1:32
CD20-targeted CAR T-Cell therapy for patients with indolent B-cell NHL
Mazyar Shadman • 10 Dec 2023
1:06
Zanubrutinib in patients with B-cell malignancies who are acalabrutinib-intolerant
Mazyar Shadman • 10 Dec 2023
3:09
Retrospective analysis of clinical outcomes in pts with LBCL receiving CAR-T or autoSCT while in CR
Mazyar Shadman • 10 Dec 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals